Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C
Mohammad Reza Zali
1
, *
,
Hamid Mohaghegh Shalmani
2
,
Mohsen Norouzinia
2
,
Amir Hooshang MohammadAlizadeh
2
,
Azita Nowroozi
2
and
Negar Behrouz
2
1 Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), zali@ams.ac.ir, Tehran, IR.Iran
2 Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, IR.Iran
*
Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), zali@ams.ac.ir, Tehran, IR.Iran. Email:
zali@ams.ac.ir
Hepatitis Monthly: 4 (7) ; 75-78 Article Type: Research Article
To Cite:
Zali
M, Shalmani
H, Norouzinia
M, MohammadAlizadeh
A, Nowroozi
A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C,
Hepat Mon.
Online ahead of Print
; 4(7):75-78.
Abstract
Background and Aim: Pegylation of interferon alfa-2a is a new modality for treatment of chronic hepatitis C. This clinical trial was conducted to evaluate the efficacy and safety of PEG IFN in combination with ribavirin in CHC patients.Methods: Fifty seven patients with HCV RNA in serum, persistently elevated ALT and chronic C hepatitis on liver biopsy enrolled to this study. The patients received PEG IFN 180 micg per week plus ribavirin 10-15 mg/kg per day.Results: HCV RNA was negative in 37 patients (74%) after three months of beginning of study (EVR) and SVR occurred in 50% of all patients.Conclusion: Peginterferon alfa-2a plus ribavirin is safe and effective in treatment of naïve patients and relapsers.
Keywords:
Hepatitis C, Pegylated interferon alfa-2a, Ribavirin, Therapy
© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Except where otherwise noted, this work is licensed under
Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments